Novel Molecules in Diabetes Melitus, Dyslipidemia and Cardiovascular Disease / / edited by Cosmin Mihai Vesa, Simona Gabriela Bungau.
The purpose of this issue is to present the impact in clinical practice as well as in medical research of novel molecules that have been introduced in the treatment of diabetes mellitus, dyslipidemia, and cardiovascular disease. The topic focuses on the improvements in disease outcomes as well as th...
Saved in:
TeilnehmendeR: | |
---|---|
Place / Publishing House: | [Place of publication not identified] : : MDPI - Multidisciplinary Digital Publishing Institute,, 2023. |
Year of Publication: | 2023 |
Language: | English |
Physical Description: | 1 online resource (152 pages) |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
id |
993607574304498 |
---|---|
ctrlnum |
(CKB)4960000000468867 (NjHacI)994960000000468867 (EXLCZ)994960000000468867 |
collection |
bib_alma |
record_format |
marc |
spelling |
Novel Molecules in Diabetes Melitus, Dyslipidemia and Cardiovascular Disease / edited by Cosmin Mihai Vesa, Simona Gabriela Bungau. [Place of publication not identified] : MDPI - Multidisciplinary Digital Publishing Institute, 2023. 1 online resource (152 pages) text txt rdacontent computer c rdamedia online resource cr rdacarrier Description based on online resource; title from PDF title page (MDPI - Multidisciplinary Digital Publishing Institute, viewed July 26, 2023). The purpose of this issue is to present the impact in clinical practice as well as in medical research of novel molecules that have been introduced in the treatment of diabetes mellitus, dyslipidemia, and cardiovascular disease. The topic focuses on the improvements in disease outcomes as well as the numerous beneficial effects of use of certain medications such as GLP-1 agonists, dual GLP-1/ GIP agonists, and SGLT-2 inhibitors for diabetes mellitus treatment; PCSK9 inhibitors and small interfering RNA (siRNA) molecules for dyslipidemia; and antiaggregants, oral anticoagulants, scubitril/valsartan, and non-steroidal mineralocorticoid receptor agonists or dapagliflozin in cardiovascular diseases. We believe that the number of real-life studies and in vivo and in vitro research of the effects of these drugs is quite low at the moment, leading to a lack of understanding of the complex molecular effects and pleiotropic effects of these medications, as well as incomplete knowledge regarding the repurposing of these drugs in clinical practice. Thus, this Special Issue is incredibly topical and important, and we look forward to your submissions which will help to clarify the issues surrounding such drugs. Cardiovascular system Diseases. 3-0365-7684-3 Vesa, Cosmin Mihai, editor. Bungau, Simona Gabriela, editor. |
language |
English |
format |
eBook |
author2 |
Vesa, Cosmin Mihai, Bungau, Simona Gabriela, |
author_facet |
Vesa, Cosmin Mihai, Bungau, Simona Gabriela, |
author2_variant |
c m v cm cmv s g b sg sgb |
author2_role |
TeilnehmendeR TeilnehmendeR |
title |
Novel Molecules in Diabetes Melitus, Dyslipidemia and Cardiovascular Disease / |
spellingShingle |
Novel Molecules in Diabetes Melitus, Dyslipidemia and Cardiovascular Disease / |
title_full |
Novel Molecules in Diabetes Melitus, Dyslipidemia and Cardiovascular Disease / edited by Cosmin Mihai Vesa, Simona Gabriela Bungau. |
title_fullStr |
Novel Molecules in Diabetes Melitus, Dyslipidemia and Cardiovascular Disease / edited by Cosmin Mihai Vesa, Simona Gabriela Bungau. |
title_full_unstemmed |
Novel Molecules in Diabetes Melitus, Dyslipidemia and Cardiovascular Disease / edited by Cosmin Mihai Vesa, Simona Gabriela Bungau. |
title_auth |
Novel Molecules in Diabetes Melitus, Dyslipidemia and Cardiovascular Disease / |
title_new |
Novel Molecules in Diabetes Melitus, Dyslipidemia and Cardiovascular Disease / |
title_sort |
novel molecules in diabetes melitus, dyslipidemia and cardiovascular disease / |
publisher |
MDPI - Multidisciplinary Digital Publishing Institute, |
publishDate |
2023 |
physical |
1 online resource (152 pages) |
isbn |
3-0365-7684-3 |
callnumber-first |
R - Medicine |
callnumber-subject |
RC - Internal Medicine |
callnumber-label |
RC667 |
callnumber-sort |
RC 3667 N684 42023 |
illustrated |
Not Illustrated |
dewey-hundreds |
600 - Technology |
dewey-tens |
610 - Medicine & health |
dewey-ones |
616 - Diseases |
dewey-full |
616.1 |
dewey-sort |
3616.1 |
dewey-raw |
616.1 |
dewey-search |
616.1 |
work_keys_str_mv |
AT vesacosminmihai novelmoleculesindiabetesmelitusdyslipidemiaandcardiovasculardisease AT bungausimonagabriela novelmoleculesindiabetesmelitusdyslipidemiaandcardiovasculardisease |
status_str |
n |
ids_txt_mv |
(CKB)4960000000468867 (NjHacI)994960000000468867 (EXLCZ)994960000000468867 |
carrierType_str_mv |
cr |
is_hierarchy_title |
Novel Molecules in Diabetes Melitus, Dyslipidemia and Cardiovascular Disease / |
author2_original_writing_str_mv |
noLinkedField noLinkedField |
_version_ |
1796653275522531329 |
fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>02360nam a2200289 i 4500</leader><controlfield tag="001">993607574304498</controlfield><controlfield tag="005">20230728202123.0</controlfield><controlfield tag="006">m o d </controlfield><controlfield tag="007">cr |||||||||||</controlfield><controlfield tag="008">230728s2023 xx o 000 0 eng d</controlfield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(CKB)4960000000468867</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(NjHacI)994960000000468867</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(EXLCZ)994960000000468867</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">NjHacI</subfield><subfield code="b">eng</subfield><subfield code="e">rda</subfield><subfield code="c">NjHacl</subfield></datafield><datafield tag="050" ind1=" " ind2="4"><subfield code="a">RC667</subfield><subfield code="b">.N684 2023</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">616.1</subfield><subfield code="2">23</subfield></datafield><datafield tag="245" ind1="0" ind2="0"><subfield code="a">Novel Molecules in Diabetes Melitus, Dyslipidemia and Cardiovascular Disease /</subfield><subfield code="c">edited by Cosmin Mihai Vesa, Simona Gabriela Bungau.</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">[Place of publication not identified] :</subfield><subfield code="b">MDPI - Multidisciplinary Digital Publishing Institute,</subfield><subfield code="c">2023.</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 online resource (152 pages)</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">computer</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">online resource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="588" ind1=" " ind2=" "><subfield code="a">Description based on online resource; title from PDF title page (MDPI - Multidisciplinary Digital Publishing Institute, viewed July 26, 2023).</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">The purpose of this issue is to present the impact in clinical practice as well as in medical research of novel molecules that have been introduced in the treatment of diabetes mellitus, dyslipidemia, and cardiovascular disease. The topic focuses on the improvements in disease outcomes as well as the numerous beneficial effects of use of certain medications such as GLP-1 agonists, dual GLP-1/ GIP agonists, and SGLT-2 inhibitors for diabetes mellitus treatment; PCSK9 inhibitors and small interfering RNA (siRNA) molecules for dyslipidemia; and antiaggregants, oral anticoagulants, scubitril/valsartan, and non-steroidal mineralocorticoid receptor agonists or dapagliflozin in cardiovascular diseases. We believe that the number of real-life studies and in vivo and in vitro research of the effects of these drugs is quite low at the moment, leading to a lack of understanding of the complex molecular effects and pleiotropic effects of these medications, as well as incomplete knowledge regarding the repurposing of these drugs in clinical practice. Thus, this Special Issue is incredibly topical and important, and we look forward to your submissions which will help to clarify the issues surrounding such drugs.</subfield></datafield><datafield tag="650" ind1=" " ind2="0"><subfield code="a">Cardiovascular system</subfield><subfield code="x">Diseases.</subfield></datafield><datafield tag="776" ind1=" " ind2=" "><subfield code="z">3-0365-7684-3</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Vesa, Cosmin Mihai,</subfield><subfield code="e">editor.</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Bungau, Simona Gabriela,</subfield><subfield code="e">editor.</subfield></datafield><datafield tag="906" ind1=" " ind2=" "><subfield code="a">BOOK</subfield></datafield><datafield tag="ADM" ind1=" " ind2=" "><subfield code="b">2023-08-05 08:49:11 Europe/Vienna</subfield><subfield code="f">system</subfield><subfield code="c">marc21</subfield><subfield code="a">2023-07-01 21:33:43 Europe/Vienna</subfield><subfield code="g">false</subfield></datafield><datafield tag="AVE" ind1=" " ind2=" "><subfield code="i">DOAB Directory of Open Access Books</subfield><subfield code="P">DOAB Directory of Open Access Books</subfield><subfield code="x">https://eu02.alma.exlibrisgroup.com/view/uresolver/43ACC_OEAW/openurl?u.ignore_date_coverage=true&portfolio_pid=5346552080004498&Force_direct=true</subfield><subfield code="Z">5346552080004498</subfield><subfield code="b">Available</subfield><subfield code="8">5346552080004498</subfield></datafield></record></collection> |